Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these...

Full description

Bibliographic Details
Main Authors: Pernelle Lavaud, Clément Dumont, Constance Thibault, Laurence Albiges, Giulia Baciarello, Emeline Colomba, Ronan Flippot, Alina Fuerea, Yohann Loriot, Karim Fizazi
Format: Article
Language:English
Published: SAGE Publishing 2020-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920978134

Internet

https://doi.org/10.1177/1758835920978134

Similar Items